Search results
Showing 6436 to 6450 of 7706 results
Low-intensity pulsed ultrasound to promote fracture healing (IPG374)
This guidance has been updated and replaced by:
- Low-intensity pulsed ultrasound to promote healing of fresh fractures at low risk of non-healing (NICE interventional procedures guidance 621)
- Low-intensity pulsed ultrasound to promote healing of fresh fractures at high risk of non-healing (NICE interventional procedures guidance 622)
- low-intensity pulsed ultrasound to promote healing of delayed-union and non-union fractures (NICE interventional procedures guidance 623)
This guidance has been updated and replaced by NICE interventional procedures guidance 724.
This guidance has been updated and replaced by NICE interventional procedure guidance 377.
Endoscopic saphenous vein harvest for coronary artery bypass grafting (IPG343)
This guidance has been updated and replaced by NICE interventional procedure guidance 494.
Health app: ChatHealth communication platform in school nursing services (MIB130)
The health app briefing on ChatHealth communication platform in school nursing services has been withdrawn.
This medtech innovation briefing has been updated and replaced by NICE's early value assessment guidance on Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies.
Artificial intelligence for analysing chest X-ray images (MIB292)
This medtech innovation briefing has been updated and replaced by health technology evaluation guidance on artificial intelligence-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12).
Daylight for treating generalised anxiety disorder in adults (MIB309)
August 2023: This medtech innovation briefing (MIB) has been withdrawn at the company’s request as the evidence for the technology has moved on and the company expect to seek a NICE guidance output in due course.
Abicipar pegol for treating wet age-related macular degeneration ID1533
In development [GID-TA10511] Expected publication date: TBC
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172]
Discontinued [GID-TA10394]
Bevacizumab for untreated malignant pleural mesothelioma [ID1183]
Discontinued [GID-TA10197]
Discontinued [GID-TA10149]
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
Discontinued [GID-TA10546]